v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories

The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the three and six months ended June 30, 2026 and 2025:

 Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
Preclinical, clinical trial and other costs  $326,117   $2,142,229   $1,749,158   $3,339,263 
Research and development personnel expense(1)   323,760    305,057    709,883    696,504 
General and administrative personnel expense(2)   585,743    628,330    1,262,170    1,302,167 
Administrative and facilities expense(3)   1,100,518    875,167    1,946,141    1,459,839 
Other expense, net(4)   929,356    (16,865)   975,321    (29,450)
Total  $3,265,494   $3,933,918   $6,642,673   $6,768,323 

 

(1)   Research and development personnel costs include employee stock-based compensation expense of $17,145 and $8,613 for the three months ended June 30, 2026 and 2025, respectively, and $34,289 and $55,333 for the six months ended June 30, 2026 and 2025, respectively.
(2)   General and administrative personnel costs include employee stock-based compensation expense of $48,528 and $122,655 for the three months ended June 30, 2026 and 2025, respectively, and $100,915 and $245,310 for the six months ended June 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.
(3)   Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
(4)   Other income, net consists of interest and dividend income, realized and unrealized loss on our digital asset, and other miscellaneous income.